Zobrazeno 1 - 10
of 117
pro vyhledávání: '"G. Rubovszky"'
Autor:
G. Rubovszky, L. Torday
Publikováno v:
Annals of Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::133f8c0e0f5013a9d89c7166ab88c775
https://doi.org/10.1016/j.annonc.2023.04.004
https://doi.org/10.1016/j.annonc.2023.04.004
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Julie Lemieux, Michael Gnant, Amylou C. Dueck, Georg Pfeiler, Meritxell Bellet-Ezquerra, Antonio C. Wolff, Magdalena Schwarz, Marcus Vetter, Angela DeMichele, Kathy D. Miller, Kathy Puyana Theall, Miguel Gil-Gil, Hannes Fohler, Patrick G. Morris, Maria Koehler, Stacy L. Moulder, Matthew Bidwell Goetz, Manuel Ruiz-Borrego, Arlene Chan, Aleix Prat, G. Rubovszky, Silvia Antolin Novoa, Otto Metzger Filho, Miguel Martín, Debora Fumagalli, Erica L. Mayer, D. Lu, Fernando Henao, Christian Fesl, Eric P. Winer, Florian Fitzal, Alistair Ring, Tiffany A. Traina, Carter Dufrane, Harold J. Burstein, Sibylle Loibl, Nicholas Zdenkowski, Daniel Egle, Hope S. Rugo, Cynthia Huang Bartlett, Daniel G. Anderson, Eleftherios P. Mamounas, Alan P. Lyss, Zbigniew Nowecki
Publikováno v:
The Lancet. Oncology
Summary Background Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6787d365738e1b450b902b6d51989545
https://doi.org/10.1016/s1470-2045(20)30642-2
https://doi.org/10.1016/s1470-2045(20)30642-2
Autor:
Yen-Shen Lu, Dejan Juric, Mario Campone, Anne-Sophie Longin, David Mills, Sibylle Loibl, Masato Takahashi, Pierfranco Conte, G. Rubovszky, Ingrid A. Mayer, Hope S. Rugo, Zsuzsanna Papai, Eva Ciruelos, Bella Kaufman, H. Iwata, Celine Wilke, Samit Hirawat, Kenichi Inoue, Fabrice Andre, Toshinari Yamashita
Publikováno v:
New England Journal of Medicine. 380:1929-1940
Background PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. The PI3Kα-sp...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b5b08e822d339fd988f84b8dac8496
https://doi.org/10.1056/nejmoa1813904
https://doi.org/10.1056/nejmoa1813904
Autor:
A-S Longin, IA Mayer, Dejan Juric, S. Loibl, Eva Ciruelos, F Andre, Toshinari Yamashita, HS Rugo, Kenichi Inoue, Zsuzsanna Papai, David Mills, G. Rubovszky, Bella Kaufman, Pierfranco Conte, Y-S Lu, Masato Takahashi, H. Iwata, C. Wilke, M. Campone, Dalila Sellami
Publikováno v:
Cancer Research. 79:GS3-08
Background: Hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway can occur due to PIK3CA mutations, present in ~40% of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2—) ABC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d173f67155f06e47af1a434cc8977aa
https://doi.org/10.1158/1538-7445.sabcs18-gs3-08
https://doi.org/10.1158/1538-7445.sabcs18-gs3-08
Autor:
Eva Ciruelos, Dejan Juric, M. Campone, Kenichi Inoue, David Mills, M. Miller, Yung-Feng Lu, M. Kaper, Ingrid A. Mayer, Hope S. Rugo, Bella Kaufman, G. Rubovszky, Zsuzsanna Papai, Toshinari Yamashita, Farhat Ghaznawi, S. Loibl, Fabrice Andre, Pierfranco Conte, Masato Takahashi, H. Iwata
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(2)
Background Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancers (ABCs) and is ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a940d5d5ff8ae7863765cfaf8ac8fb
https://pubmed.ncbi.nlm.nih.gov/33309744
https://pubmed.ncbi.nlm.nih.gov/33309744
Autor:
G. Rubovszky, David Mills, M. Kaper, Dejan Juric, Hope S. Rugo, M. Campone, Fabrice Andre, H. Iwata, Ingrid A. Mayer, Bella Kaufman, Farhat Ghaznawi, S. Loibl, M. Miller, Toshinari Yamashita, Eva Ciruelos, Kenichi Inoue, Pierfranco Conte, Y-S Lu, Zsuzsanna Papai, Masato Takahashi
Publikováno v:
Annals of Oncology. 31:S1150-S1151
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af99ab3ac78f1646ab99396fae999a9a
https://doi.org/10.1016/j.annonc.2020.08.2246
https://doi.org/10.1016/j.annonc.2020.08.2246
Autor:
M. Gnant, Hannes Fohler, AM DeMichele, Kathy D. Miller, M. Martin, EP Winer, Daniel G. Anderson, Zbigniew Nowecki, Erica L. Mayer, K. Puyana Theall, S. Loibl, Christian Fesl, Harold J. Burstein, Nicholas Zdenkowski, Otto Metzger, Georg Pfeiler, Debora Fumagalli, Aleix Prat, G. Rubovszky, Amylou C. Dueck
Publikováno v:
Annals of Oncology. 31:S1145
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e4cd2673f908b95378084fbc6a97b70
https://doi.org/10.1016/j.annonc.2020.08.2240
https://doi.org/10.1016/j.annonc.2020.08.2240
Autor:
Antonia Ridolfi, M. Campone, Ines Lorenzo, Hope S. Rugo, Ingrid A. Mayer, Toshinari Yamashita, Fabrice Andre, S. Loibl, H. Iwata, Pierfranco Conte, Eva Ciruelos, G. Rubovszky, Dejan Juric
Publikováno v:
Annals of Oncology. 30:v122-v123
Background Approximately 40% of patients (pts) with HR+, HER2– BC have mutations (mut) in PIK3CA with hyperactivation of the PI3K pathway and relative endocrine resistance. In the phase 3 SOLAR-1 trial, treatment with the α-selective PI3K inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f13e0ade59a0bca5c414a4d7982f492f
https://doi.org/10.1093/annonc/mdz242.037
https://doi.org/10.1093/annonc/mdz242.037